Why the study?
Does canagliflozin prevent heart failure in patients with type 2 diabetes?
Does canagliflozin prevent heart failure in patients with type 2 diabetes?
The study identified potential mediators for the prevention of heart failure with SGLT2 inhibitors in patients with type 2 diabetes, supporting both existing and novel mechanisms.
Candidate mediators for SGLT2i HF effects in T2D warrant validation trials; should not yet change practice.
A diverse set of potential mediators of the effect of canagliflozin on heart failure were identified. Some mediating effects were anticipated, whereas others were not. The mediators that were identified support existing and novel hypothesized mechanisms for the prevention of heart failure with sodium glucose cotransporter 2 inhibitors.
No takes yet. Share an insight, caveat, or question.
Li et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: